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Statement of Translational Relevance  
With further evidence from larger cohorts, the risk of ovarian cancer algorithm (ROCA) based on 
longitudinal serum CA125 measurements could be applied to women at increased genetic/familial risk 
who elect screening for early detection of ovarian cancer. ROCA personalizes screening to a 
woman’s unique CA125 level, using each woman as her own control, resulting in a more precise 
screening test. Shifting transvaginal ultrasound from concurrent with CA125 (the present standard) to 
secondary triage only in women with abnormal ROCA results greatly reduces ultrasound-related 
false-positive tests. However, consideration of risk-reducing salpingo-oophorectomy (RRSO) upon 
completion of child bearing and when ovarian cancer risk increases above population risk is and 
should remain the current standard of care for BRCA1/2 mutation carriers. If further studies determine 
ROCA is effective, this improved approach to early detection would be available to increased risk 
women who choose, despite a strong recommendation for RRSO, to postpone their surgery.  
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Abstract 
Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven 
efficacy. Research suggests each woman has her own CA125 baseline; significant increases above 
this level may identify cancers earlier than standard 6-12 monthly CA125>35U/mL. 
Experimental Design: Data from prospective Cancer Genetics Network and Gynecologic Oncology 
Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong 
breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel 
screening strategy. Specifically, serum CA125 q3 months, evaluated using a risk of ovarian cancer 
algorithm (ROCA), detected significant increases above each subject’s baseline, which triggered 
transvaginal ultrasound. Specificity and PPV were compared with levels derived from general 
population screening (specificity 90%, PPV 10%), and stage-at-detection was compared with 
historical high-risk controls. 
Results: Specificity for ultrasound referral was 92% vs. 90% (p=0.0001), and PPV was 4.6% vs. 10% 
(p>0.10). Eighteen of 19 malignant ovarian neoplasms (prevalent=4, incident=6, RRSO=9) were 
detected via screening or risk-reducing salpingo-oophorectomy (RRSO). Amongst incident cases 
(which best reflect long-term screening performance), 3/6 invasive cancers were early-stage (I/II) 
(50% versus 10% historical BRCA1 controls; p=0.016). Six of 9 RRSO-related cases were stage I. 
ROCA flagged 3/6 (50%) incident cases before CA125 exceeded 35U/mL. Eight of 9 stages 0/I/II 
ovarian cancer patients were alive at last follow-up (median 6 years). 
Conclusions: For screened women at familial/genetic ovarian cancer risk, ROCA q3 months had 
better early-stage sensitivity at high specificity, and low yet possibly acceptable PPV compared with 
CA125>35 U/mL q6/q12 months, warranting further larger cohort evaluation. 
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Introduction 
 
Early detection of ovarian cancer with periodic CA125 blood tests and transvaginal ultrasound (TVU) 
was recommended in the US,(1, 2) but not universally,(3) for women at increased familial risk. 
Recently, the US recommendation evolved to a consideration(4) including investigational screening 
studies(5) since standard use of CA125 and TVU showed no screening efficacy(6-12), with most 
cases detected in late-stage disease.(13, 14) We conducted two pilot detection trials in women at 
increased familial risk to test a new approach to screening, estimating specificity, positive predictive 
value (PPV), and comparing the proportion detected in early-stage with the proportion in high-risk 
historical controls. To increase the proportion detected in early-stage while maintaining high test 
specificity, the new approach (i) personalized screening by detecting significant rises above each 
woman’s CA125 baseline, (ii) tested CA125 more frequently, and (iii) referred women to TVU only 
following a positive blood test.  
  
Previous CA125-based screening studies in women at familial risk have shown no improvement in 
outcomes, perhaps because they: (i) classified tests as positive only when CA125 >35 U/mL; (ii) 
tested annually; and (iii) tested with concurrent CA125 and TVU, which creates high false-positive 
rates from frequent TVUs. We addressed the first limitation by leveraging longitudinal CA125 data 
based on studies indicating that each woman’s baseline CA125 level is unique.(15-17)  ROCA 
identifies significant rises above each individual’s baseline, personalizing the test and increasing the 
likelihood of earlier disease detection, ideally before reaching the 35 U/mL threshold.(16) Specificity is 
maintained by ruling out women with high, stable CA125 values. Further exemplifying the need for a 
personalized approach we note there are significant differences between the CA125 distributions for 
post-menopausal (98th percentile=35 U/mL) and pre-menopausal (98th percentile=52 U/mL) 
women.(18)  
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Regarding the second limitation, most previous screening studies of increased-risk women evaluated 
annual testing schedules. Data regarding more frequent testing are limited.(19) Ovarian cancer 
progression from early- to late-stage disease may be too rapid for annual testing to effectively detect 
early-stage disease.(20) More frequent blood tests might increase the likelihood of detecting early-
stage disease.  
 
Finally, simultaneous testing with CA125 and TVU yields high false-positive rates, primarily due to 
benign TVU-detected adnexal masses, necessitating many surgeries to identify one true-positive.(21) 
Preliminary data suggest that using TVU as a secondary test to evaluate abnormal CA125 tests might 
significantly reduce false-positive rates.(22-26) Thus, our studies included annual TVU for all subjects 
(standard care during conduct of studies), and interim TVU only to assess abnormal ROCA results. 
 
The two prospective pilot early detection studies reported here screened increased-risk women using 
CA125-based ROCA every three months, interval TVU only for abnormal ROCA results, and annual 
screening TVU, per standard care. We use the term “increased-risk” versus “high-risk” advisedly, to 
more accurately reflect participant risk heterogeneity, with a high-risk subset (BRCA1/2 mutation 
carriers) and groups at intermediate risk between mutation carriers and the general population 
(unknown mutation status or mutation-negative/strong family-history-positive subjects).  The CGN 
and GOG studies implemented the same screening protocol and eligibility criteria; US and Australian 
CA125 testing was done in one centralized research laboratory in each country.  Multiple duplicate 
test samples were analyzed to ensure high inter-lab concordance. Study goals included evaluating 
compliance with the quarterly CA125 screening schedule and obtaining estimates of ROCA 
performance characteristics through a pre-planned combined analysis of the two studies. 
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Performance characteristics listed for the CGN study were sensitivity, specificity, and PPV, for the 
GOG study were specificity and PPV, while the combined analysis specified goals of achieving a 
specificity of at least 90% and a PPV of at least 10% (see Supplement). Optimal debulking was 
added as a study endpoint after study initiation. 
 
Methods 
These two studies have been described previously.(18, 27) The primary outcomes were specificity, 
PPV, and sensitivity for invasive ovarian cancer.  
 
Subjects 
The Cancer Genetics Network (CGN) initiated the ROCA study (NCT-00039559) to assess ROCA’s 
operating characteristics in women at increased familial/genetic risk of ovarian cancer.(28) 
Subsequently, two ovarian cancer Specialized Program on Research Excellence (SPORE) sites, two 
Early Detection Research Network (EDRN) sites, and five independent sites opened the study. 
Together, 25 sites enrolled 2,359 subjects between 2001 and 2011, yielding 6,979 woman-years of 
screening (median 2.9 yrs; range 0–10.3 yrs). This seemingly short follow-up median duration 
actually represents 9 screening episodes; 0 years indicates women who enrolled but were never 
screened. The low median and wide range of duration are due to several CGN sites having additional 
internal funds enabling screening to continue for longer periods than the other sites. Eligibility criteria 
included women from families with a deleterious BRCA1/2 mutation, and/or multiple ovarian and/or 
breast cancers in first- or second-degree blood relatives (see Supplement). Women who had 
previously undergone bilateral oophorectomy (n=278) were eligible for screening for primary 
peritoneal cancer but were excluded from this analysis. In the CGN study, BRCA1/2 results available 
at study initiation were recorded but BRCA1/2 testing was not performed as part of the study. 
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The Gynecologic Oncology Group (GOG) initiated the GOG-0199 study (NCT-00043472) as a two-
arm, non-randomized observational study of increased-risk women who chose between risk-reducing 
salpingo-oophorectomy (RRSO) and ROCA-based ovarian cancer screening. GOG-0199 had the 
same eligibility criteria as the CGN study, except that women without ovaries were ineligible. The 
GOG screening arm followed the ROCA protocol, enabling data to be combined. The GOG-0199 
screening arm enrolled 1,459 evaluable subjects into the screening cohort across 112 sites in the US 
and Australia between 2003 and 2006,(27) yielding 6,101 woman-years of screening (median 5.0yrs, 
range 0–6.9yrs). GOG-0199 participants who were BRCA1/2-unknown at study enrollment underwent 
research-based germline mutation testing; BRCA1/2 mutation status was known to study 
investigators in 99.6% of participants. All subjects in both studies signed IRB-approved informed 
consent. 
 
Screening strategy 
CA125 tests were scheduled every three months. TVU was performed annually regardless of CA125 
results as this was considered standard-of-care for high-risk women. The screening strategy 
implemented ROCA(16) which individualized the screening test for each woman. For any sequence 
of CA125 results and test intervals, ROCA calculated the chance (risk) that serum CA125 had a 
change-point profile which had increased significantly above baseline versus a flat profile which 
varies stably around the baseline (see Supplement). An increased change-point risk raised suspicion 
for an undetected tumor. All screening decisions regarding ROCA scheduling or more detailed 
ultrasound or gynecologic evaluation were based on the ROCA risk level, not the most recent CA125 
test result. After each new CA125, ROCA risk was re-calculated, adding the current CA125 to all 
previous results, subject’s age and menopausal status, and the subject was re-triaged: normal-risk 
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women (<1% risk of having ovarian cancer) returned in three months for the next CA125; those with 
an intermediate risk (1-10%) were referred for TVU; and those with an elevated risk (>10%) received 
TVU and evaluation by a gynecologic oncologist or study site PI. Consequently, women with above-
normal risks were referred to more intensive follow-up, commensurate with their risk score. The 
updated ROCA resulted in rapid referral of women with CA125 levels rising significantly above their 
baseline, including increases within the so-called normal range (≤35 U/mL), to TVU or TVU with 
gynecologic oncologist review. This strategy avoided further diagnostic evaluation among women with 
levels >35 U/mL, but stable compared with their baseline. Thus, the extra information contained in 
ROCA-interpreted longitudinal CA125 levels potentially increases screening test sensitivity, while 
retaining the same specificity versus a fixed cut-off applied to the last CA125 value. 
 
All US serum CA125 values were measured by the Massachusetts General Hospital Clinical 
Laboratory Research Core using the Elecsys CA125-II assay (Roche Diagnostics, Indianapolis, IN). 
 
Since randomized trials with an unscreened arm were judged unethical in women at increased 
familial/genetic risk, this study compared specificity and PPV with standards set in normal risk 
populations, compared the proportion of cancers detected in early-stage with published historical 
results from high-risk women,(13, 14) and internally compared ROCA with the single threshold rule of 
>35 U/mL in our data set. Annual specificity of the ROCA blood test was the proportion of women 
without ovarian cancer not referred to TVU per year. PPV was the proportion of ovarian cancers 
amongst women undergoing study-indicated pelvic surgery. Early-stage was defined as FIGO (1988) 
surgical stages 0/I/II, since the five-year survival rate in unselected ovarian cancer patients is strongly 
correlated with stage (94%, 91%, 86%, 80%, 76%, 67%, for stages IA, IB, IC, IIA, IIB, IIC, and 45%, 
39%, 35%, 18% for stages IIIA, IIIB, IIIC, and IV, respectively). The largest survival drop occurs 
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between stages IIC and IIIA; most ovarian cancers (66.5%) are detected as late-stage disease (III/IV). 
A surgical procedure was considered screen-indicated if it was preceded by an intermediate or 
elevated ROCA test.  
 
Since women with BRCA1/2 mutations are at very high-risk of ovarian cancer, standard care involves 
strongly considering RRSO following completion of childbearing and at an age when ovarian cancer 
risk increases above population risk.(5) Study subjects were permitted to elect RRSO in the absence 
of worrisome symptoms or a positive screening test at any time during the study; 696 subjects in the 
combined study underwent oophorectomy for any reason while on study. While screening trials for 
normal-risk women consider the positive predictive value (PPV) – the fraction of ovarian cancers 
among surgeries following a positive screening test – as the primary efficacy metric, PPV may be less 
important when a woman at increased risk reaches the point at which standard care recommends 
RRSO for OC risk management, a practice change which followed two 2005 reports.(29, 30) All CGN 
subjects were followed for ≥one year after their last screening test with a final questionnaire that 
ascertained all cancer diagnoses. GOG subjects were planned to undergo 5 years of screening, with 
cancer outcomes monitored by open-ended annual questionnaires. Invasive ovarian, fallopian tube, 
or primary peritoneal cancer were the endpoints for this analysis; in aggregate, we designated them 
“ovarian cancer.” Each study had central review of all ovarian surgical specimens(31), including all 
501 RRSOs, by central pathologists (CGN: Bell, MGH; Welch, BWH; GOG-0199: Sherman, NCI; 
Ioffe, U Maryland; Ronnett, Johns Hopkins). Among 696 surgical specimens reviewed, there were two 
instances (0.3%) – one from each study - in which an ovarian cancer was identified by central review 
(GOG: Sherman; CGN: Welch) but not by the study site pathologist. For one of these cases, central 
review interpreted the lesion as a serous tubal intraepithelial carcinoma (STIC), while the site 
identified high-grade dysplasia. 
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Statistical Methods 
Proportions were compared with standards set from screening normal risk women (specificity, PPV) 
and historical control reports (sensitivity), using an exact binomial test.(32) Estimates of the 
proportion of increased-risk women with non-screen-detected early-stage ovarian cancer are difficult 
to obtain from historical reports. Unlike populations at general risk, there are no registries containing 
population-based estimates of clinical and pathological features for women at increased risk. Also, 
there is no standard definition of increased risk, and the understanding of which women are at 
increased risk has changed over time. Ovarian cancer stage distributions in BRCA1/2 germline 
mutation carriers are a reasonable surrogate for stage distribution in women at increased risk. For 
comparison with the results in the two screening studies, the population value of the proportion of 
early-stage invasive ovarian cancers amongst BRCA1 carriers was 10%, calculated from the 
weighted combination of 8%(n=88) and 14%(n=50) from two pathology series reported before 
screening was common(13, 14). Screening studies of women at increased risk(33) differ in their 
definitions of “increased risk” and/or in their screening regimen, so it is difficult to aggregate their 
results. We used stage distribution of unselected normal-risk ovarian cancer patients as an additional 
comparison, ascertained via SEER 9 2001 tumor registry data, in which the proportion of early-stage 
disease was 33.5%, with SEER stages “local” and “regional” corresponding to FIGO stages I & II.  
 
Results 
 
Study Population Characteristics 
Table 1 summarizes race and ethnicity, and Table 2 provides ovarian cancer risk factors at baseline. 
Among 3,449 eligible subjects, 41% had prior breast cancer, 83% had a breast cancer family history 
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(34% included one or more premenopausal breast cancers), 47% had an ovarian cancer family 
history, and 34% reported a family history of both. Most subjects were white (92%), and 20% were of 
Ashkenazi Jewish descent. More than half (59%) were premenopausal, 80% were parous, 10% had a 
pre-enrollment hysterectomy; by self-report, 77% had used oral contraceptives (median=5 years; 
range 0–52), and 30% had used hormone replacement therapy (median=3 years; range 0–44). The 
CGN cohort comprised 58% of participants, contributing 6,979 woman-years of screening (53%), 
while the GOG cohort contributed 6,101 years of screening. Twenty percent of CGN study 
participants reported a deleterious mutation.  The probability of carrying a BRCA1/2 mutation was 
estimated using BRCAPRO(34) for the CGN cohort, yielding an average of 21%, indicating that 
reporters of BRCA mutation status were likely representative of the whole CGN cohort. In screening 
subjects from GOG-0199, 20% had a documented positive BRCA1/2 test. The similarity in mutation 
prevalence between the two study cohorts suggests that the common eligibility criteria yielded study 
groups of equivalent genetic risk. The distribution of variables in Table 1 was similar in both study 
populations. 
Screening Results 
Supplementary Table 1 lists the number of subjects by year for which ROCA was used to evaluate 
CA125 profiles and triage by risk. On average, 92% of ROCA evaluations indicated a normal risk (for 
the study population); these subjects returned for their next regularly scheduled test. Less than 7% 
had an intermediate risk and were referred for a study-indicated TVU (92% annual specificity vs 90%, 
p=0.0001), while 1% of ROCA tests had an elevated risk level, and were referred to TVU and 
evaluation by a gynecologic oncologist or study PI (99% annual specificity). Based on screening 
model characteristics, we had estimated that 1-2% of ROCA assays would recommend the highest 
level of intervention, a rate that was achieved.  
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The high frequency of CA125 testing was a crucial screening trial element; we hypothesized that 
increased frequency would improve detecting early-stage ovarian cancer. The protocol-specified 
ROCA testing frequency was every three months (i.e., four times/year). The average actual testing 
frequency (ratio of total CA125 tests to total screening years) was one every four months (three 
times/year). Each subsequent CA125 test was scheduled three months from last test date if risk was 
normal, or three months from normal ultrasound date if the risk was intermediate or elevated. Despite 
the high frequency of testing, 88% of CA125 tests were conducted within one month of their 
scheduled time, demonstrating a very high screening compliance rate.  
 
Cancer Outcomes (Sensitivity) 
Table 2 lists the 19 malignant ovarian neoplasms (18 invasive and one intraepithelial carcinoma) 
identified during the two screening studies: ovary=8, fallopian tube=6 (including 1 serous tubal 
intraepithelial carcinoma (STIC)), ovary+fallopian tube=3, primary peritoneal carcinoma=2. Eleven of 
15 serous cancers were high-grade. Three low malignant potential (LMP) tumors, one each in 
incident, elective RRSO, and prevalent subgroups, were identified, all in stage I; none were known to 
have a BRCA mutation. The LMPs were omitted from all subsequent analyses. The proportion of 
study-detected ovarian cancers in early-stage (stages 0/I/II), ROCA detection prior to CA125 >35 
U/mL, and optimal debulking defined the outcomes potentially positively affected by early detection. 
Screening would not be expected to modify stage at detection of a large proportion of existing but 
currently undetected tumors, i.e., among prevalent cases (first study-related CA125 test was elevated 
or part of a rising pattern).(35) Effective screening for incident cases, which arose during rather than 
before screening initiation, would be expected to yield an increased proportion of early-stage cases.  
Nine women were diagnosed with ovarian cancers at elective RRSO (none of their screening tests 
had produced a surgical recommendation); thus, we separated surgically-detected cases from 
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screen-detected cases. We analyzed our data stratified by incident, elective RRSO, and prevalent 
cancer diagnoses. Of 19 ovarian carcinomas identified, six were incident, nine elective RRSO, and 
four prevalent cases. All prevalent cases were ROCA screen-detected and positive by 
CA125>35U/mL rule. None of the four prevalent invasive cases was early-stage, statistically 
commensurate with the historical rate of 10% early stage disease in high-risk women. Two stage IV 
prevalent cases were not optimally debulked. Six (67%) of the nine RRSO-related carcinoma cases 
were early-stage, including one non-invasive STIC (Stage 0). All RRSO patients with clinically occult 
cancers were optimally debulked.  
 
The six incident cases reflect long-term screening program outcomes; five were screen-detected and 
one was clinically-detected. Three of the six incident cancers were screen-detected in early-stage 
(50%; 95%CI=12%-88%; 50% versus 10% historical BRCA1 cases, p=0.016; 50% versus 33.5% 
normal risk cases, p>0.10). Of the 3 early-stage invasive incident cases, two had a BRCA1 mutation, 
and one had both BRCA1 and BRCA2 mutations. The two late-stage (IIIC) cases were BRCA1/2 
mutation-negative. Of the 3 early-stage cases, two were identified when the last CA125 was still <35 
U/mL. In 3/6 cases (50%), ROCA signaled intervention (TVU or TVU plus gynecologic oncologist 
consultation) prior to CA125 >35 U/mL. All 6 incident cases were optimally debulked. Eight of 9 
women with stages 0/I/II ovarian cancers detected in this study were alive at last known follow-up 
(range 5-9yrs), including the patient with STIC, who is alive and disease-free 5 years after surgery. Of 
the 3 ROCA-detected stages I/II cases, all were alive at follow-up, 2 at 8 years and one at 6 years. 
696 subjects had ovarian surgery during the course of study, of whom 195 had surgery preceded by 
an intermediate or elevated ROCA. Of those surgeries, 9 had ovarian cancer, yielding a conservative 
PPV of 4.6% (95%CI=2.1–8.6%). Among the 186 false-positive surgeries following a non-normal 
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ROCA, the median age was 48 years. Among the 501 elective RRSOs, there were 9 ovarian cancer 
cases, yielding an incidence of 2% (95%CI=0.8–3.4%). 
 
Figure 1 illustrates how longitudinal ROCA testing detected a stage IIB ovarian cancer despite CA125 
remaining <35 U/mL (red line). ROCA interpreted the CA125 level at the last 2 tests (red circles) as 
significantly above this woman’s baseline, resulting in referral to ultrasound. The second ultrasound 
was abnormal, which generated a surgical recommendation and diagnosis of a stage IIB ovarian 
cancer, which was optimally debulked.  
 
Discussion 
This study shows that ROCA-driven q3 months CA125 testing among increased-risk women was 
associated with a high specificity >90% and a low but possibly acceptable PPV <10%. This strategy 
yielded an increased proportion of early-stage invasive ovarian cancer among incident cases 
compared with historical invasive BRCA1 cases (50% versus 10%; p=0.016) and compared with 
cases from the general population (50% versus 33.5%; p>0.10) though not significantly. We have 
focused sensitivity analysis and discussion on this study sub-group because outcomes for incident 
cases comprise the best metric for long-term screening. ROCA detected 5/6 (83%) incident cases, 
with three (50%) of the 6 detected prior to CA125 exceeding the standard cut-point of 35 U/mL. 
These results are commensurate with recent data from the UK Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS) general population trial,(35) in which 50% of incident cases were also 
detected by ROCA, based on annual CA125 testing prior to CA125 >35 U/mL, and 89% of incident 
cases were screen-detected.(35) The efficient use of longitudinal CA125 information, with half of the 
incident cases detected by ROCA prior to CA125 exceeding the standard cut-point, the 3-month 
frequency of scheduled CA125 tests, and using TVU only to triage women with abnormal ROCA 
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results, represent the innovations in the current screening strategy which resulted in a significantly 
higher proportion of early-stage cases detected in this combined analysis of two screening trials 
compared with historical BRCA1 controls.  
 
ROCA quantitatively assessed whether recent CA125 results were significantly elevated above each 
woman’s baseline. Figure 1 illustrates a change-point at year 3.5, with a steady increase in five 
subsequent CA125 tests. In contrast, under the screening rule based on >35 U/mL cut-off, no 
ultrasound would have been performed until after year 6, by which time the ovarian cancer might 
have progressed to a more advanced stage. In addition to personalizing the test, our results were 
obtained using CA125 testing scheduled every 3 months, twice the maximum frequency of CA125 
testing that was considered under standard care for increased-risk women.(4) Consequently, 9/10 
non-RRSO-related invasive cancers were screen-detected, with only one clinically-detected case (an 
additional 9 were RRSO-detected), and 17/19 (89%; 95%CI 67%, 99%) cancer patients were 
optimally debulked; only the two prevalent stage IV cases were not optimally debulked. This 
compares with 58% optimally debulked in the unscreened normal-risk population (weighted average 
from Cochrane Collaboration Report, Table 1: Studies post-2001).(36) Since optimal debulking has 
been shown to increase survival significantly,(36, 37) this may be an additional beneficial outcome for 
ROCA q3 months screening.  
 
Despite early predictions that women would not comply with testing every three months, a very high 
proportion (88%) of CA125 tests was obtained within one month of their scheduled phlebotomy date. 
On average, our increased-risk study participants underwent CA125 testing every 4 months. These 
very high compliance rates are encouraging, as they demonstrate the clinical feasibility of this 
intensive strategy, and likely reflect the fact that increased-risk women who choose to retain their 
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ovaries and enroll in a screening trial are very highly motivated to adhere to screening 
recommendations.  
 
Our study has limitations. Lacking an unscreened control group to which ROCA participants can be 
compared comprises a significant methodological limitation, but at the time this study was initiated it 
was judged ethically unacceptable since combined CA125/TVU screening had become the de facto 
standard of care for increased-risk women, despite unproven efficacy. This represents a difficult 
methodological constraint: it is unlikely that a prospective, randomized screening trial will be 
performed in increased-risk women, despite universal recognition that such a design is required to 
assess disease-specific mortality reduction, the gold-standard screening endpoint. Therefore, stage 
at detection compared with historical controls was used as a surrogate comparison. However, 
detecting 3/6 incident carcinoma cases in early-stage does not prove that these women will live 
longer. UKCTOCS was a randomized screening trial,(25) but it implemented annual ROCA-based 
CA125 screening in only normal-risk women; its results will only indirectly be related to assessing q3 
months ROCA in high-risk women. Our study complements the UKCTOCS report by providing results 
on increased-risk women. Additional data regarding screen-detected incident cases from ROCA 
screening of increased-risk populations are needed before our finding of an increase in the proportion 
of early-stage cases is conclusive. Further studies will also help determine whether interpreting 
CA125 values with ROCA or the higher q3 months frequency of CA125 testing or both modifications 
of standard CA125 screening are responsible for the increase in early-stage detection.  
 
A second caveat follows from the low power of our primary analysis, since it is based on only five 
incident invasive ovarian cancers. But nine additional cancers were detected among women who 
elected RRSO in the absence of symptoms or a ROCA-based recommendation for surgery. Had that 
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option not been available to study participants, the number of analyzable incident events would have 
been meaningfully larger. We had estimated that >20 ovarian cancers would develop in this 
genetically-predisposed population of women, but the anticipated increased statistical power relative 
to studying general population subjects was reduced significantly because 14.5% (501/3,448) of 
participants elected RRSO without a screening-related surgical recommendation, since it is standard 
practice to counsel genetically at-risk women to consider RRSO once childbearing has been 
completed and at an age when ovarian cancer risk increases above population risk. Furthermore, 
when these protocols were designed, BRCA-negative women with only breast cancer in their family 
were study-eligible due to their hypothesized increased risk of ovarian cancer. These women are now 
not anticipated to be at substantially increased ovarian cancer risk,(29, 38) thus further reducing the 
anticipated power of the study. We are exploring opportunities to pool our results with those of other 
ROCA-based ovarian cancer screening trials, such as the UK Familial Ovarian Cancer Screening 
Study (UKFOCSS),(12) in an effort to increase statistical power for sensitivity and PPV.  
 
RRSO cases also present an interpretation issue for screening sensitivity. An alternative 
interpretation of our data is that the RRSO cases were missed by ROCA, and therefore the sensitivity 
for early-stage disease for incident cases was 29% (4/14 = 5 incident ROCA-detected cases + 9 
cases detected on RRSO) – that is, ROCA missed all 9 RRSO cases (3–25 weeks from last CA125 
test to surgery, median 9.3). However, the aim of early detection is to diagnose cancers in early-stage 
disease, ideally stages 0/I. If the RRSO cases comprised all late-stage disease, then the 
interpretation that ROCA missed these cases would be reasonable but, in fact, 6/9 RRSO cases were 
early-stage cancers. RRSO “censored” these cases before they reached late-stage disease. Another 
analytic alternative would be to combine RRSO cases with incident cases to estimate the proportion 
identified during the screening trial in early-stage disease. This interpretation combines 3/6 incident 
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cases with 6/9 RRSO cases for a combined early-stage proportion of 60% (9/15; 95%CI: 32%-84%), 
even higher than the estimate based on incident cases alone (50%), yields a much tighter confidence 
interval and therefore greater statistical significance. Thus, we judge our decision to restrict the early-
stage estimate to only incident cases as conservative and appropriate.  
 
Another reason we analyzed the RRSO cases separately was because a secondary sensitivity 
outcome compares ROCA to a CA125 threshold and the RRSO action censored these cases prior to 
either ROCA being positive or CA125 exceeding 35U/mL, thus providing no information regarding 
which occurred first. The large proportion of early-stage cancers among the RRSO cases provides 
further encouragement to considering RRSO in this population, and reason to hope that some of 
these women will become long-term, disease-free survivors.  
 
The low (5%) screening-related positive predictive value indicates that twenty surgical procedures 
were performed for each ovarian cancer detected, and comprises a limitation that warrants special 
comment. We believe this estimate may nonetheless be acceptable among BRCA1/2 mutation 
carriers after they complete childbearing and reach the age at which RRSO is regarded as standard 
of care, yet who chose to continue screening. The PPV standard set from consideration of screening 
trials in the general population is not appropriate in a population for which RRSO is strongly 
recommended and widely practiced. The low PPV does require caution for women with false-positive 
results who are below the age at which RRSO is recommended among BRCA1/2 carriers or who 
have not completed child bearing. Thus, it is reassuring that the median age among false-positive 
cases was 47 years. 
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Due to incomplete BRCA mutation ascertainment in the CGN cohort (a budgetary constraint), our 
data do not permit drawing conclusions about the utility of this screening strategy in women from 
mutation-negative/strong family history kindreds. However, among the 19 cancers, there were 13 
BRCA1, 1 BRCA2, and 1 subject with a mutation in both genes; 3 were BRCA1/2 negative; and 1 
subject was untested. Thus, limiting frequent ROCA screening to BRCA mutation carriers would still 
miss some cases (3/18=17% of cases tested) in this increased-risk cohort.  
 
Another caveat is that real world application would require adjusting for CA125 variation between 
laboratories, a concern mitigated by very high inter-laboratory correlation.(39) A further limitation: 
ROCA screening, even in high-risk populations, requires screening many women to detect a few 
early-stage cases. In the combined studies, 3 early-stage invasive incident cases were detected that 
may have been clinically detected in late-stage without screening in 13,080 woman-years, i.e. 23 
early-stage cases per 100,000 screened women (0.023%), a crucial input for a future cost-benefit 
assessment. 
 
Finally, while ROCA detected cases in an earlier stage than screening with a single CA125 >35U/mL 
in this study, all were detected in stage II (IIA,IIA,IIB), which has much better survival than stages 
III/IV, but significantly lower survival than stage I. Better blood tests and secondary imaging must be 
developed to detect cases in stages 0/I. Many high-grade serous ovarian cancers in BRCA1/2 
carriers are believed to originate in the distal fimbriated end of the fallopian tube,(40) and proteins 
secreted by fallopian tube epithelium may provide promising biomarker candidates.(41) TVU was 
negative in 3/6 prevalent and 2/5 incident cases, consonant with fallopian tubes being difficult to 
visualize with TVU and suggesting that a better imaging test is required. The CA125 protein is not 
shed by 20% of ovarian cancers, so a CA125-based ROCA cannot detect such cancers. Developing 
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a biomarker panel which covers the full ovarian cancer spectrum, and interpreting those data with 
longitudinal, ROCA-like models, might improve the performance of screening programs aimed at 
detecting early-stage disease, as shown with FDA-authorized multiple marker diagnostic tests for 
pelvic masses (ROMA, OVA1).(42, 43) Approaches that may enable earlier detection through 
analysis of DNA in lower genital tract samples are also under investigation.(44, 45)  
 
In summary, our study provides the following encouraging evidence: (1) women at increased-risk who 
agree to an intensive screening regimen are compliant; (2) more frequent CA125 testing interpreted 
by ROCA is associated with a high specificity and a significant increase in the detection of early-stage 
incident ovarian cancer compared with published data from historical controls; (3) ROCA detected 
50% of incident cases prior to the standard cut-point of 35 U/mL; (4) ROCA detection is associated 
with a high optimal debulking rate in incident cases; and (5) 8 of 9 women with early-stage cancer 
were alive at last follow-up. Importantly, we believe these observations do not represent a sufficient 
basis for introducing this screening strategy into clinical practice as an alternative to RRSO. While 
even the mixed evidence on the effectiveness of ovarian cancer screening is welcome news,(35, 46) 
we still regard consideration of RRSO upon completion of childbearing and reaching the 
recommended age as the current standard of care for BRCA1/2 mutation carriers. It is essential to 
recall that even an effective screening program cannot reduce the risk of developing ovarian cancer; 
its benefit can only derive from earlier detection and improved survival.  However, there still remains a 
significant subset of increased-risk women who choose to retain their ovaries and tubes once their 
families are complete, despite being fully informed of the benefits of RRSO, including significantly 
reduced risks of both ovarian cancer and breast cancer, and significantly improved overall 
survival.(47) Our data suggest that for women who choose screening instead of RRSO, ROCA 
screening with quarterly CA125 tests, plus TVU as a secondary screen for those with an elevated risk 
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score, appeared to be a significant improvement over q6-12 monthly CA125 screening with a single 
cut-point, such as 35 U/mL. However, due to the small number of incident cases, further evidence 
from larger cohorts is required before ROCA with q3 months screening tests can be confidently 
recommended as a replacement for annual or six-monthly testing for women choosing screening. 
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Table 1: Race, ethnicity, and ovarian cancer risk factors for all subjects in the two studies 
Variable N 
(CGN) 
% of Total 
(CGN) 
N 
(GOG) 
% of Total 
(GOG) 
Race* 
17 1 
  
            Asian 16 1 
            Black 73 4 33 2 
            White 1,761 88 1,399 96 
            Other 120 6 10 1 
            Unknown/not reported 21 1 0 0 
Hispanic Ethnicity 
1,945 98 
 
1,380 
 
95             Not Hispanic or Latino 
            Hispanic or Latino 46 2 21 1 
            Unknown/not reported 57 4 0 0 
Ashkenazi Jewish Descent 
365 18 
313 21             Yes 
            No 1,604 81 1,058 73 
            Unknown 22 1 87 6 
Menopause Status     
            Pre-menopause 1,117 56 919 63 
            Post-menopause 874 44 539 37 
Number of Intact Ovaries     
            2 1,862 94 1,418 97 
            1 102 5 40 3 
            Unknown/not reported 27 1   
Hysterectomy*     
            Yes 246 12 84 6 
            No 1,715 86 1,368 94 
            Unknown 30 2 6 0 
Ever Pregnant**     
            Yes 1,610 81 1,142 78 
            No 340 17 273 19 
            Unknown 41 2 43 3 
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Ever Use Oral Contraceptives     
            Yes, currently using 200 10 176 12 
             Yes, not currently using 1,354 68 929 64 
            Never used 395 20 353 24 
            Unknown 42 2 0 0 
Ever Use Hormone Replacement**     
            Yes, currently using 202 10 90 6 
            Yes, not currently using 442 22 317 22 
            No 1,214 61 1,045 72 
            Unknown 133 7 6 0 
Personal History of Breast Cancer     
            Yes 843 42 586 40 
            No 1,122 56 872 60 
            Unknown 26 1 0 0 
Family History of Breast Cancer     
            Yes 1,669 84 1,190 82 
            No 297 15 241 17 
            Unknown 25 1 27 2 
Family History of Ovarian Cancer     
            Yes 876 44 745 51 
            No 1,311 66 918 63 
            Unknown 25 1 16 1 
Cohort     
 1,991 100 1,458 100 
 
* With at least one ovary intact at enrollment. 
   ** Percentages may not add to 100 due to rounding. 
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Table 2: Ovarian cancers detected during the course of two screening studies 
Case  
# 
Prevalent
/Incident 
Age 
at Dx 
Mutation 
status 
Primary 
site 
ROCA 
+ve 
ROCA 
vs 
>35 TVU
Opt 
Debulk Histology Stg Grd* 
1 Incident 41 BRCA1+ BRCA2+ 
Ovary & 
Fallopian tube Y  B Pos Y 
Endometrioid 
(90%), serous, clear 
cell 
IIB 2-3 
2 Incident 62 BRCA1 Ovary & Fallopian tube Y = Pos Y 
Papillary serous 
carcinoma IIA 3 
3 Incident 65 negative Ovary N NA Neg Y Serous carcinoma IIIC 3 
4 Incident 42 BRCA1 Fallopian tube Y B NA Y Undifferentiated carcinoma IIA 3 
5 Incident 64 negative Ovary Y B Pos Y Serous carcinoma IIIC 3 
6 Incident 49 BRCA1 Ovary Y = Neg Y Serous carcinoma IIIC 3 
7 Elective RRSO 65 not tested Ovary N N/A NA Y 
Serous 
psammocarcinoma IIIA 2 
8 Elective RRSO 41 BRCA1 Fallopian tube N N/A Neg 
Not 
applicable 
Tubal intraepithelial 
carcinoma 0 0 
9 Elective RRSO 63 BRCA2 Ovary N N/A NA NA 
Endometrioid 
carcinoma I 2 
10 Elective RRSO 43 BRCA1 Fallopian tube N N/A Neg Y 
Serous carcinoma IA 3 
11 Elective RRSO 50 BRCA1 Fallopian tube N N/A NA Y 
carcinoma, 
unspecified IC 3 
12 Elective RRSO 49 BRCA1 Ovary N N/A Neg Y 
Serous carcinoma IC 3 
13 Elective RRSO 46 BRCA1 Ovary N N/A Neg Y 
Serous carcinoma IIIC 2 
14 Elective RRSO 59 negative Fallopian tube N N/A NA Y 
Serous carcinoma IA 2 
15 Elective RRSO 42 BRCA1 Peritoneum N NA Neg Y 
Serous carcinoma III 3 
16 Prevalent 51 BRCA1 Ovary & Fallopian tube Y B Neg N 
Papillary serous 
carcinoma IVB 3 
17 Prevalent 40 BRCA1 Peritoneum Y = Pos N Peritoneal serous carcinoma IIIC 3 
18 Prevalent 48 BRCA1 Ovary Y = Pos Y Serous carcinoma IIIC 2 
19 Prevalent 81 BRCA1 Fallopian tube Y A Pos Y Serous carcinoma IIIC 3 
Abbreviations: 
Dx: diagnosis 
ROCA +ve: ROCA recommended surgical evaluation. 
ROCA vs >35: was ROCA abnormal prior to CA125 exceeding 35 U/mL? 
 B: ROCA abnormal before CA125 exceeded 35 U/mL 
 =: ROCA became abnormal and CA125 exceeded 35 U/mL simultaneously 
 A: ROCA became abnormal after CA125 exceeded 35 U/mL 
TVU: transvaginal ultrasound 
Opt Debulk: patient optimally-debulked 
Stg: FIGO stage 
Grd: histologic grade 
Neg: negative 
Pos: positive 
NA: not available – ovaries not visualized on TVU 
RRSO: risk-reducing salpingo-oophorectomy 
* WHO classification divides serous carcinoma into two categories (LG, HG), but WHO classification was not available at 
the time of pathology review. All Grade 3 serous carcinomas would be HG by WHO. 
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LEGENDS 
 
 
 
Figure 1: Early detection of ovarian cancer via ROCA even though CA125 remains below 35 U/mL. 
The consistent increase in CA125 from the nadir (blue arrow) increases the calculated risk of having 
ovarian cancer with each additional CA125 test until the risk is elevated (red circles) with a 
recommendation of a trans-vaginal ultrasound. Surgery was recommended at the second ultrasound 
and a mixed endometrioid and serous ovarian cancer (stage IIB) detected. 
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